title: Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
abstract: BACKGROUND
  Bisphosphonate therapy remains the most effective way of controlling Paget's disease of bone (PD). Along with salmon calcitonin, etidronate has been the mainstay of therapy for approximately 20 years. However, the advent of newer bisphosphonates with different molecular actions on osteoclasts warrants a reevaluation of optimal treatment.
  
  
  OBJECTIVE
  At a symposium of the Western Osteoporosis Alliance, physicians with experience in the management of PD met to review currently available information and generate this consensus statement as a guideline for clinicians and a source of information for health care payers.
  
  
  METHODS
  All available randomized, double-blind, controlled studies that compared the efficacy of newer bisphosphonates with that of etidronate in the treatment of PD were identified through a search of MEDLINE using the terms Paget's disease, bisphosphonates, pamidronate, etidronate, alendronate, risedronate, tiludronate, clodronate, calcitonin, and salmon calcitonin. Because no such studies have been conducted for pamidronate, clodronate, or calcitonin, these drugs were not included in the analysis.
  
  
  CONCLUSIONS
  The consensus of the symposium was that etidronate has little place in the modern management of PD. Newer bisphosphonates such as alendronate and risedronate provide significant therapeutic advantages over etidronate, both in the extent of reduction in bone-specific alkaline phosphatase (BSAP) and/or total serum alkaline phosphatase (SAP) and in the duration of remission, as measured by normalization of BSAP/SAP. In the absence of a direct comparison between alendronate and risedronate in the treatment of PD, physician choice is likely to be based on personal experience, relative cost, and differences in dosing.
authors.affiliation: Department of Medicine, University of British Columbia, Vancouver, Canada. will_drake@canada.com
authors.forename: W M
authors.initials: WM
authors.lastname: Drake
authors.forename: D L
authors.initials: DL
authors.lastname: Kendler
authors.forename: J P
authors.initials: JP
authors.lastname: Brown
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D000469:Alkaline Phosphatase / Q000097:blood; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000191:economics / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D010001:Osteitis Deformans / Q000097:blood / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D000068296:Risedronic Acid; D013997:Time Factors
chemical_list: D004164:Diphosphonates; D000469:Alkaline Phosphatase; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate